Cefepime monotherapy for febrile neutropenia in patients with lung cancer

Hiroshi Saito, Kosuke Takahashi, Motoyasu Okuno, Hideo Saka, Kazuyoshi Imaizumi, Yoshinori Hasegawa, Yoshimasa Tanikawa, Masashi Yamamoto, Hiroyuki Taniguchi, Joe Shindoh, Ryujiro Suzuki, Kaoru Shimokata

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


We assessed the efficacy and safety of cefepime monotherapy (1 g intravenously every 8 h) for febrile neutropenia in patients with lung cancer in a multi-institutional phase II study. Patients treated with chemotherapy with or without radiotherapy for lung cancer were eligible for this study. Other eligibility criteria included fever (temperature of ≥38.0 °C) and an absolute neutrophil count of <500/mm3 or <1000/mm3 with an expected decline to <500/mm3 within the next 48 h. Risk assessment was performed using the Multinational Association of Supportive Care in Cancer risk-index score. Cefepime 1 g was given intravenously every 8 h. The primary endpoint was the response rate at the end of cefepime therapy. Co-administration of granulocyte-colony-stimulating factor was permitted. Of 54 patients enrolled, 39 were classified in the low-risk group and 15 in the high-risk group. Overall response rate was 78% (95% CI: 64.4-88.0%). The response rates were 85% (95% CI: 69.5-94.1%) in the low-risk group and 60% (95% CI: 32.3-83.7%) in the high-risk group, respectively. One patient died from septic shock due to Enterobacter cloacae bacteremia. There was no significant adverse event. Cefepime 1 g intravenously every 8 h appears to be effective for febrile neutropenia in patients with lung cancer, especially in those with low-risk febrile neutropenia, and is well tolerated.

Original languageEnglish
Pages (from-to)365-369
Number of pages5
JournalJournal of Infection and Chemotherapy
Issue number6
Publication statusPublished - 06-2014

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Cefepime monotherapy for febrile neutropenia in patients with lung cancer'. Together they form a unique fingerprint.

Cite this